Nexalin blog

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company's non-invasive, frequency-based deep brain...

23 January, 2024

Nexalin Technology Unveils Next-Generation HALO™ Clarity

A new neurostimulation device to combat the growing global mental health epidemic Designed for drug-free treatment of mental health conditions from the privacy of one's home with virtual monitoring by a physician ...

11 January, 2024

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Results published in General Psychiatry, a leading peer-reviewed journalHOUSTON, TEXAS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today reported the results of a study in patients with treatment-resistant depression (TRD), concerning the potential therapeutic...

18 December, 2023

Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

HOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory Board ( "Advisory Board") to support its non-invasive, frequency-based, deep-brain stimulation devices within U.S. government...

25 October, 2023

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures

Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health diseaseHOUSTON, TX, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or...

16 October, 2023

Nexalin’s Big Biz Show Interview

To watch the interview click on the link HERE and setup an account.  Forward the video to 36 minute to begin the Nexalin interview.  ...

02 September, 2023

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

New migraine data builds on prior clinical studies in depressionHOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of...

07 August, 2023

Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time

HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participating in a live interview with the "Big Biz Show," an Emmy Award-winning nationally syndicated...

03 August, 2023

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced the formation of a new division, to be called "Nexalin America," aimed at fostering relationships within the U.S. Department of Defense, U.S. Department of...

26 July, 2023

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBIHOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced that Company's...

10 July, 2023